CINECA IRIS Institutional Research Information System

GENUARDI, Elisa
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.146
EU - Europa 1.417
AS - Asia 681
AF - Africa 25
SA - Sud America 6
OC - Oceania 4
Totale 4.279
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.116
IT - Italia 521
CN - Cina 308
SG - Singapore 212
SE - Svezia 175
IE - Irlanda 141
AT - Austria 133
DE - Germania 85
FR - Francia 78
FI - Finlandia 63
DK - Danimarca 52
UA - Ucraina 49
IN - India 35
GB - Regno Unito 33
JP - Giappone 27
CA - Canada 25
VN - Vietnam 24
KR - Corea 21
SN - Senegal 21
NL - Olanda 17
BE - Belgio 16
ID - Indonesia 16
PL - Polonia 15
RU - Federazione Russa 14
HK - Hong Kong 10
GR - Grecia 8
IR - Iran 7
UZ - Uzbekistan 7
ES - Italia 6
CH - Svizzera 4
PK - Pakistan 4
AU - Australia 3
BR - Brasile 3
SA - Arabia Saudita 3
TR - Turchia 3
CZ - Repubblica Ceca 2
MX - Messico 2
PR - Porto Rico 2
RO - Romania 2
TG - Togo 2
AR - Argentina 1
CI - Costa d'Avorio 1
CL - Cile 1
CU - Cuba 1
GH - Ghana 1
IL - Israele 1
KH - Cambogia 1
KW - Kuwait 1
LU - Lussemburgo 1
MD - Moldavia 1
MY - Malesia 1
NZ - Nuova Zelanda 1
RS - Serbia 1
VE - Venezuela 1
Totale 4.279
Salva come PNG Salva come JPEG
Città #
Chandler 310
Santa Clara 177
Singapore 177
Dublin 140
Ashburn 135
Beijing 134
Torino 132
Vienna 132
Ann Arbor 117
Fairfield 102
Florence 83
Turin 76
Nyköping 73
Woodbridge 71
Houston 67
Wilmington 66
Dearborn 56
Villeurbanne 46
Medford 39
Seattle 39
Princeton 37
Cambridge 35
Columbus 35
Jacksonville 33
San Mateo 31
Fremont 30
Munich 29
Guangzhou 26
Redwood City 22
Helsinki 20
Washington 17
Jakarta 16
Pisa 16
Bologna 15
Dong Ket 15
Brussels 14
Ottawa 14
Shanghai 12
Boston 11
Hyderabad 11
Milan 11
Rome 10
Los Angeles 9
Norwalk 9
Toronto 9
Warsaw 9
Boardman 8
Hebei 8
Nanjing 8
Chennai 7
Hangzhou 7
Nutley 7
San Diego 7
Chengdu 6
Duncan 6
Hong Kong 6
Naples 6
Philadelphia 6
Tokyo 6
Wayne 6
Casalecchio di Reno 5
Falls Church 5
Lappeenranta 5
Ningbo 5
Pune 5
Seoul 5
Brescia 4
Dronten 4
Noto 4
Saint Petersburg 4
San Mauro Torinese 4
Zhengzhou 4
Campi Bisenzio 3
Carmagnola 3
Changchun 3
Ivrea 3
Kunming 3
Monza 3
New York 3
San Francesco 3
San Francisco 3
Shenyang 3
São Paulo 3
Umeå 3
Wuhan 3
Amsterdam 2
Assago 2
Baran 2
Berlin 2
Bilbao 2
Bresso 2
Chicago 2
Cocconato 2
Coimbatore 2
Collegeville 2
Des Moines 2
Edinburgh 2
Falkenstein 2
Flero 2
Flushing 2
Totale 2.885
Salva come PNG Salva come JPEG
Nome #
HashClone: a new tool to quantify the minimal residual disease in B-cell lymphoma from deep sequencing data 392
Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program 279
Highly sensitive MYD88 l265p mutation detection by droplet digital polymerase chain reaction in waldenström macroglobulinemia 206
Centralized Biobanking Supports Hematology Clinical Trials: the new challenge of the University of Torino 195
Telomere loss in Philadelphia-negative hematopoiesis after successful treatment of chronic myeloid leukemia: evidence for premature aging of the myeloid compartment. 140
Applying data warehousing to a phase III clinical trial from the Fondazione Italiana Linfomi (FIL) ensures superior data quality and improved assessment of clinical outcomes. 137
Early Relapse Risk in Patients with Newly Diagnosed Multiple Myeloma Characterized by Next-generation Sequencing 137
TELOMERES SHORTEN DURING CHRONIC LYMPHOCYTIC LEUKEMIA(CLL) EVOLUTION: AN ANALYSIS ON 88 CASES 133
New Molecular Technologies for Minimal Residual Disease Evaluation in B-Cell Lymphoid Malignancies 132
Telomere length is an independent predictor of survival, treatment requirement and Richter’s syndrome transformation in chronic lymphocytic leukemia 115
Ficoll-hypaque separation vs whole blood lysis: Comparison of efficiency and impact on minimal residual disease analysis 114
A longitudinal analysis of chromosomal abnormalities in disease progression from MGUS/SMM to newly diagnosed and relapsed multiple myeloma 112
Progressive Telomere Shortening Is Part of the Natural History of Chronic Lymphocytic Leukemia (CLL) and Impacts Clinical Outcom 110
Minimal Residual Disease Detection by Droplet Digital PCR in Multiple Myeloma, Mantle Cell Lymphoma, and Follicular Lymphoma: A Comparison with Real-Time PCR 107
Delphi, a Data Warehouse to Discover Associations between Variables in Clinical Trials: Application to the Fondazione Italiana Linfomi (FIL) MCL0208 Phase III Trial 107
PROGRESSIVE TELOMERE SHORTENING DURING THE NATURAL HISTORY OF CHRONIC LYMPHOCYTIC LEUKEMIA 104
Expression of telomeric proteins in chronic lymphocytic leukemia (CLL) 103
Telomere lenght measurement in the clinically oriented research setting: a comparison between Southern blot (SB), real time quantitative PCR (RQ-PCR) and FLOW-FISH (FF) 102
MYD88L265P MUTATION DETECTION IN WALDENSTRÖM MACROGLOBULINEMIA BY DROPLET DIGITAL PCR: MINIMAL RESIDUAL DISEASE MONITORING AND CHARACTERIZATION ON CIRCULATING FREE DNA 102
Progressive telomere shortening occurs during the natural history of chronic lymphocytic leukemia (CLL) and associates to outcome 97
Long-term results of the GIMEMA VEL-03-096 trial in MM patients receiving VTD consolidation after ASCT: MRD kinetics' impact on survival 96
The Engineered MIPI (e-MIPI), a Candidate Data-Mining Based Mantle Cell Lymphoma Prognostic Index Developed from the Dataset of the Fondazione Italiana Linfomi (FIL) MCL0208 Phase III Trial 96
Progressive telomere shortening is part of the natural history of chronic lymphocytic leukaemia and impacts clinical outcome: Evidences from long term follow-up 88
Telomere length is an independent predictor of survival, treatment requirement and Richter's syndrome transformation in chronic lymphocytic leukemia 87
Comparison of two real-time quantitative polymerase chain reaction strategies for minimal residual disease evaluation in lymphoproliferative disorders: correlation between immunoglobulin gene mutation load and real-time quantitative polymerase chain reaction performance. 84
Comparison of different DNA extraction methods from peripheral blood cells: advices from the Fondazione Italiana Linfomi - MRD Network. 84
Minimal residual disease (MRD) in non-Hodgkin lymphomas: Interlaboratory reproducibility on marrow samples with very low levels of disease within the FIL (Fondazione Italiana Linfomi) MRD Network 83
Minimal Residual Disease in Indolent Lymphomas: A Critical Assessment 79
Application of the Euro Clonality next-generation sequencing-based marker screening approach to detect immunoglobulin heavy chain rearrangements in mantle cell lymphoma patients: first data from the Fondazione Italiana Linfomi MCL0208 trial 72
Targeted locus amplification to detect molecular markers in mantle cell and follicular lymphoma 67
Clinical implications and prognostic role of minimal residual disease detection in follicular lymphoma 66
null 64
Punctual and kinetic MRD analysis from the Fondazione Italiana Linfomi MCL0208 phase III trial in mantle cell lymphoma 62
Droplet digital PCR quantification of mantle cell lymphoma follow-up samples from four prospective trials of the european MCL network 61
Dissecting MRD Kinetics By Automated Computational Analysis to Improve Outcome Prediction in Mantle Cell Lymphoma: A Bioinformatic Substudy from the Fondazione Italiana Linfomi (FIL) MCL0208 Clinical Trial 53
Immunoglobulin kappa deleting element rearrangements are candidate targets for minimal residual disease evaluation in mantle cell lymphoma 49
MYD88L265P Detection in IgM Monoclonal Gammopathies: Methodological Considerations for Routine Implementation 48
Genomic and immune determinants of resistance to daratumumab-based therapy in relapsed refractory multiple myeloma 42
A Clinical Prognostic Model Based on Machine Learning from the Fondazione Italiana Linfomi (FIL) MCL0208 Phase III Trial 40
Quality Assessment for PCR-based Minimal Residual Disease in Lymphoma: 10 Years of Cross-laboratory Standardization Process Within the Fondazione Italiana Linfomi MRD Network 39
MODULATION OF THE IMMUNE MICROENVIROMENT IN MULTIPLE MYELOMA PATIENTS TREATED WITH DARATUMUMABBASED THERAPY: TUMOR CELL-EXTRINSIC EFFECTS OF DARATUMUMAB TREATMENT 30
Rituximab-based pre-emptive treatment of molecular relapse in follicular and mantle cell lymphoma. 30
Candidate germline biomarkers of lenalidomide efficacy in mantle cell lymphoma: the Fondazione Italiana Linfomi MCL0208 trial 29
In pancreatic cancer patients, chemotherapy reshapes the gene expression profile and antigen receptor repertoire of T lymphocytes and enhances their effector response to tumor-associated antigens 20
Stem cell collection and hematological recovery in the Fondazione Italiana Linfomi (FIL) MCL0208 clinical trial 16
Local radiotherapy and measurable residual disease-driven immunotherapy in patients with early-stage follicular lymphoma (FIL MIRO): final results of a prospective, multicentre, phase 2 trial 6
Totale 4.415
Salva come PNG Salva come JPEG
Categoria #
all - tutte 14.145
article - articoli 0
book - libri 0
conference - conferenze 3.191
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 17.336
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020413 0 0 0 0 0 64 67 56 41 51 59 75
2020/2021551 75 49 56 29 38 27 29 33 47 37 67 64
2021/2022622 19 15 15 47 36 27 83 39 15 84 150 92
2022/2023909 92 107 18 101 59 215 57 67 91 27 35 40
2023/2024439 68 86 35 27 27 63 12 32 1 21 18 49
2024/2025652 22 54 77 113 318 68 0 0 0 0 0 0
Totale 4.415